| Direct Competitor Comparison | |
|---|
| AMRN | MRK | Industry |
|---|
| Market Cap: | 1.05B | 142.92B | 32.64B |
|---|
| Employees: | 111 | 83,000 | 35.15k |
|---|
| Qtrly Rev Growth (yoy): | N/A | -0.09 | 1.74 |
|---|
| Revenue (ttm):
| 2.34M | 46.21B | 13.93B |
|---|
| Gross Margin (ttm): | 0.45 | 0.65 | 0.83 |
|---|
| EBITDA (ttm): | -157.38M | 16.36B | 5.72B |
|---|
| Operating Margin (ttm):
| -67.50 | 0.21 | 0.20 |
|---|
| Net Income (ttm): | -153.06M | 6.02B | N/A |
|---|
| EPS (ttm): | -1.04 | 1.96 | 2.00 |
|---|
| P/E (ttm): | N/A | 24.15 | 24.04 |
|---|
| PEG (5 yr expected): | -0.07 | 5.22 | 1.15 |
|---|
| P/S (ttm): | 449.28 | 3.09 | 3.04 |
|---|
|
| MRK = Merck & Co. Inc. | | Industry = Drug Manufacturers - Other | |
| Biotechnology Companies Ranked By Sales | |
|---|
|
| Company | Symbol | Price | Change | Market Cap | P/E |
|---|
| Amgen Inc. | AMGN | 104.24 | 0.00 | 78.18B | 17.64 |
|---|
| Genentech, Inc. | "Private" |
|---|
| Biogen Idec Inc. | BIIB | 231.33 | 0.00 | 54.91B | 36.71 |
|---|
| Genzyme Corporation | "Private" |
|---|
| Merck Serono S.A. | "Private" |
|---|
| Gilead Sciences Inc. | GILD | 56.47 | 0.00 | 86.14B | 31.62 |
|---|
| MedImmune, L.L.C. | "Private" |
|---|
| Life Technologies Corporation | LIFE | 73.68 | 0.00 | 12.68B | 31.19 |
|---|
| Teva Pharmaceutical Industries Limited | TEVA | 40.21 | 0.00 | 34.26B | 20.07 |
|---|
| Sandoz International GmbH | "Private" |
|---|
|
| Generic Drugmakers Ranked by Sales | |
|---|
|
| Company | Symbol | Price | Change | Market Cap | P/E |
|---|
| Actavis, Inc. | ACT | 130.20 | 0.00 | 16.63B | N/A |
|---|
| Ranbaxy Laboratories Limited | "Private" |
|---|
| Mylan, Inc. | MYL | 31.23 | 0.00 | 11.90B | 20.86 |
|---|
| Pfizer Inc. | PFE | 28.78 | 0.00 | 204.14B | 13.78 |
|---|
| Johnson & Johnson | JNJ | 88.59 | 0.00 | 248.84B | 24.06 |
|---|
| GlaxoSmithKline plc | GSK | 52.65 | 0.00 | 127.52B | 19.24 |
|---|
| Sanofi | SNY | 55.05 | 0.00 | 145.70B | 27.13 |
|---|
| Novartis AG | NVS | 74.63 | 0.00 | 183.38B | 18.94 |
|---|
| Roche Holding AG | RHHBY | 64.71 | 0.00 | 219.62B | 21.66 |
|---|
| AstraZeneca PLC | AZN | 51.71 | 0.00 | 64.64B | 11.44 |
|---|
|
| Drugmakers Ranked By Sales | |
|---|
|
| Company | Symbol | Price | Change | Market Cap | P/E |
|---|
| Abbott Laboratories | ABT | 37.72 | 0.00 | 58.80B | 11.50 |
|---|
| Bristol-Myers Squibb Company | BMY | 44.06 | 0.00 | 72.37B | 49.90 |
|---|
|
| News on Direct Competitors | |
|---|
- MRK
- Merck signs $5 billion share buyback agreement with Goldman Sachs Reuters Wed 2:07am
- MRK
- Finding the Next Big Blockbuster Drug Accesswire Thu, May 16
- MRK
- StockCall Scrutinizes PFE, MRK, JNJ, ABBV, and ZGNX Accesswire Wed, May 15
- MRK
- Analysis: Drugmakers face more scrutiny of discordant U.S. prices Reuters Fri, May 10
- MRK
- Leading Active Companies in the News: Crown Marketing (CWNM), Nuvilex (NVLX), Elite Pharmaceuticals (ELTP), Cannabis Science (CBIS), Merck (MRK) Accesswire Thu, May 9
All headlines for these symbols... Currency in USD. | |
|
1.03%